发布求助
文献互助 智能选刊 最新文献

Current Opinion in Pharmacology最新文献

筛选
英文 中文
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis 补体途径是新生血管性老年黄斑变性介导的视网膜下纤维化的治疗靶点
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-06-01 Epub Date: 2024-03-30 DOI: 10.1016/j.coph.2024.102448
Heping Xu , Caijiao Yi , Mei Chen
{"title":"The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis","authors":"Heping Xu ,&nbsp;Caijiao Yi ,&nbsp;Mei Chen","doi":"10.1016/j.coph.2024.102448","DOIUrl":"https://doi.org/10.1016/j.coph.2024.102448","url":null,"abstract":"<div><p>Neovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no medication to prevent or treat the condition. Here, we discussed recent advances in the pathogenesis of nAMD-mediated macular fibrosis, with a focus on the role of the complement system. We further proposed approaches to target the complement system for the management of macular fibrosis and highlighted the area of further research for future clinical applications of complement-based therapy.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"76 ","pages":"Article 102448"},"PeriodicalIF":4.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489224000183/pdfft?md5=fbf295b621546072e3f80c3a7d39177b&pid=1-s2.0-S1471489224000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140328504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the endocannabinoid system for the management of low back pain 针对内源性大麻素系统治疗腰背痛
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1016/j.coph.2024.102438
Mary A. Hopkins , Brian E. McGuire , David P. Finn
{"title":"Targeting the endocannabinoid system for the management of low back pain","authors":"Mary A. Hopkins ,&nbsp;Brian E. McGuire ,&nbsp;David P. Finn","doi":"10.1016/j.coph.2024.102438","DOIUrl":"https://doi.org/10.1016/j.coph.2024.102438","url":null,"abstract":"<div><p>Low back pain (LBP) is a major unmet clinical need. The endocannabinoid system (ECS) has emerged as a promising therapeutic target for pain, including LBP. This review examines the evidence for the ECS as a therapeutic target for LBP. While preclinical studies demonstrate the potential of the ECS as a viable therapeutic target, clinical trials have presented conflicting findings. This review underscores the need for innovative LBP treatments and biomarkers and proposes the ECS as a promising avenue for their exploration. A deeper mechanistic understanding of the ECS in LBP could inform the development of new pain management strategies.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102438"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489224000080/pdfft?md5=07597a8c72a12dbf07bf7fe9f395c1f7&pid=1-s2.0-S1471489224000080-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139936644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastrointestinal issue: Advances in gastrointestinal oncology 胃肠道问题：胃肠道肿瘤学的进展
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI: 10.1016/j.coph.2024.102437
Jeroen Dekervel, Angelica Petrillo
{"title":"Gastrointestinal issue: Advances in gastrointestinal oncology","authors":"Jeroen Dekervel,&nbsp;Angelica Petrillo","doi":"10.1016/j.coph.2024.102437","DOIUrl":"https://doi.org/10.1016/j.coph.2024.102437","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102437"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139936645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial overview: New and revitalized old targets in metabolic disease 编辑综述：代谢性疾病中的新靶点和重获新生的旧靶点
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.1016/j.coph.2024.102434
Jacob B. Hansen, Ivana Novak
{"title":"Editorial overview: New and revitalized old targets in metabolic disease","authors":"Jacob B. Hansen,&nbsp;Ivana Novak","doi":"10.1016/j.coph.2024.102434","DOIUrl":"10.1016/j.coph.2024.102434","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102434"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139554989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid raft disruption as an opportunity for peripheral analgesia 脂质筏破坏为外周镇痛提供了机会。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.1016/j.coph.2024.102432
Andrea Kinga Nehr-Majoros , Ágnes Király , Zsuzsanna Helyes , Éva Szőke
{"title":"Lipid raft disruption as an opportunity for peripheral analgesia","authors":"Andrea Kinga Nehr-Majoros ,&nbsp;Ágnes Király ,&nbsp;Zsuzsanna Helyes ,&nbsp;Éva Szőke","doi":"10.1016/j.coph.2024.102432","DOIUrl":"10.1016/j.coph.2024.102432","url":null,"abstract":"<div><p><span><span><span>Chronic pain conditions are unmet medical needs, since the available drugs, opioids, non-steroidal anti-inflammatory/analgesic drugs and adjuvant analgesics do not provide satisfactory therapeutic effect in a great proportion of patients. Therefore, there is an urgent need to find novel targets and novel therapeutic approaches that differ from classical pharmacological receptor antagonism. Most ion channels and receptors involved in pain sensation and processing such as Transient Receptor Potential<span> ion channels, opioid receptors, P2X purinoreceptors and </span></span>neurokinin 1 receptor are located in the </span>lipid raft regions of the plasma membrane. Targeting the </span>membrane lipid<span> composition and structure by sphingolipid or cholesterol depletion might open future perspectives for the therapy of chronic inflammatory, neuropathic or cancer pain, most importantly acting at the periphery.</span></p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102432"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estrogen related receptor alpha: Potential modulator of age-related macular degeneration 雌激素相关受体α：老年性黄斑变性的潜在调节剂
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-03-05 DOI: 10.1016/j.coph.2024.102439
Fatima Massare Somers , Goldis Malek
{"title":"Estrogen related receptor alpha: Potential modulator of age-related macular degeneration","authors":"Fatima Massare Somers ,&nbsp;Goldis Malek","doi":"10.1016/j.coph.2024.102439","DOIUrl":"https://doi.org/10.1016/j.coph.2024.102439","url":null,"abstract":"<div><p>To develop effective therapies for complex blinding diseases such as age-related macular degeneration (AMD), identification of mechanisms involved in its initiation and progression is needed. The estrogen-related receptor alpha (ESRRA) is an orphan nuclear receptor that regulates several AMD-associated pathogenic pathways. However, it has not been investigated in detail in the ocular posterior pole during aging or in AMD. This review delves into the literature highlighting the significance of ESRRA as a molecular target that may be important in the pathobiology of AMD, and discusses data available supporting the targeting of this receptor signaling pathway as a therapeutic option for AMD.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102439"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside 靶向 TRP 通道缓解疼痛：从临床到床边的现有证据综述
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-03-11 DOI: 10.1016/j.coph.2024.102447
Ari-Pekka Koivisto , Thomas Voets , Michael J. Iadarola , Arpad Szallasi
{"title":"Targeting TRP channels for pain relief: A review of current evidence from bench to bedside","authors":"Ari-Pekka Koivisto ,&nbsp;Thomas Voets ,&nbsp;Michael J. Iadarola ,&nbsp;Arpad Szallasi","doi":"10.1016/j.coph.2024.102447","DOIUrl":"https://doi.org/10.1016/j.coph.2024.102447","url":null,"abstract":"<div><p>Several decades of research support the involvement of transient receptor potential (TRP) channels in nociception. Despite the disappointments of early TRPV1 antagonist programs, the TRP family remains a promising therapeutic target in pain disorders. High-dose capsaicin patches are already in clinical use to relieve neuropathic pain. At present, localized injections of the side-directed TRPV1 agonist capsaicin and resiniferatoxin are undergoing clinical trials in patients with osteoarthritis and bone cancer pain. TRPA1, TRPM3, and TRPC5 channels are also of significant interest. This review discusses the role of TRP channels in human pain conditions.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102447"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1471489224000171/pdfft?md5=e71d630d360072b78e623fcc3092cb04&pid=1-s2.0-S1471489224000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140095804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial overview: “Purinergic immune cell regulation reveals novel pharmacological targets” 编辑综述："嘌呤能免疫细胞调控揭示了新的药理靶点
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.1016/j.coph.2024.102435
Wolfgang Junger, Carola Ledderose
{"title":"Editorial overview: “Purinergic immune cell regulation reveals novel pharmacological targets”","authors":"Wolfgang Junger,&nbsp;Carola Ledderose","doi":"10.1016/j.coph.2024.102435","DOIUrl":"10.1016/j.coph.2024.102435","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102435"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel treatments for dry eye syndrome 干眼症的新疗法。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.1016/j.coph.2024.102431
Esther Roucaute , Marcela Huertas-Bello , Alfonso L. Sabater
{"title":"Novel treatments for dry eye syndrome","authors":"Esther Roucaute ,&nbsp;Marcela Huertas-Bello ,&nbsp;Alfonso L. Sabater","doi":"10.1016/j.coph.2024.102431","DOIUrl":"10.1016/j.coph.2024.102431","url":null,"abstract":"<div><p>Dry eye syndrome (DES) is a prevalent and multifactorial disease that leads to a self-perpetuating cycle of inflammation and damage to the ocular surface. This results in symptoms such as redness, burning, and blurred vision, which can negatively affect a patient's quality of life. While treatments are available to manage DES, they only temporarily relieve symptoms. Furthermore, long-term use of certain medications can cause harm to the ocular surface. Therefore, there is a need for safer and effective treatments for DES. This review highlights the latest advancements in DES therapy, providing valuable insights into ongoing efforts to improve patient outcomes.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102431"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139567295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial overview: Endocrine and metabolic diseases (2023) 编辑综述：内分泌与代谢疾病》（2023 年）
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2024-04-01 Epub Date: 2024-01-29 DOI: 10.1016/j.coph.2024.102436
Ivana Bjelobaba, Stephanie Constantin
{"title":"Editorial overview: Endocrine and metabolic diseases (2023)","authors":"Ivana Bjelobaba,&nbsp;Stephanie Constantin","doi":"10.1016/j.coph.2024.102436","DOIUrl":"10.1016/j.coph.2024.102436","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"75 ","pages":"Article 102436"},"PeriodicalIF":4.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139579115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书